I still have some shares, decided to hold for the tv show, they moved it from 3/27 to 4/10... this weekend...
STGI's Cortisol/Anticortisol Concept in Treating Diseases Rescheduled for Cable TV Airing in USA, Switzerland, Germany and Austria
Business Wire - March 24, 1999 08:01
Jump to first matched term
LAS VEGAS--(BW HealthWire)--March 24, 1999--Steroidogenesis Inhibitors International (OTCBB:STGI) today announced new dates for the Company's television appearances on three cable TV networks including CNBC which will feature STGI's cortisol/anti-cortisol approach to treating diseases, some of them with no known treatment at the present.
Orginally scheduled for March 27, Michael Jackson's interview with STGI's President, Dr. Alfred T. Sapse and Executive Vice President, Dr. Janet Greeson, on "Investing in America," a sponsored program, will instead air on April 10 at 2:00PM EST in the United States. On or about April 25 the same program will be aired in Europe with a German voice-over translation intended primarily for German-speaking populations in Switzerland, Germany and Austria.
The show will present, for the first time to a lay audience in United States and Europe, the essence of the Cortisol/Anticortisol Concept developed by Dr. Sapse in 1984. This concept was presented previously only to medical researchers at the World Congresses and Symposiums in Berlin, Amsterdam, Tokyo and more recently in Paris, Vancouver and Las Vegas.
Viewers of this TV program will learn the role played by Cortisol, the powerful hormone manufactured by the adrenal gland, in causing disease or major symptoms of diseases and the potential therapeutic role of the anticortisol drugs. Dr. Sapse will discuss STGI's anticortisol drug ANTICORT(TM) as the forerunner of a new class of drugs intended to enhance the effectiveness of presently used medications treating AIDS, heart attacks, ulcers, hypertension, diabetes and psoriasis as well as its own potential effectiveness in alleviating or reducing symptoms due to cortisol in disorders such as cancers, multiple sclerosis (MS), Lou Gehrig's disease (ALS), aging and Alzheimer's; diseases where there is no effective treatment at the present time.
STGI is a pharmaceutical R&D Corporation engaged in the development of anti-cortisol drugs to be used in diseases/conditions associated with elevated levels of the immunosuppressive hormone cortisol. STGI's flagship anti-cortisol drug ANTICORT has been approved by the FDA to be clinically tested in an HIV+ population -- a condition often associated with "high cortisol", which apparently plays a major role in the destruction of the immune system as encountered in HIV+ and AIDS.
This release may include "forward-looking statement" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1034. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com.
CONTACT: STEROIDOGENESIS PERFORMANCE STRATEGIES
Janet Greeson, Ph.D. Richard L. Brown/Chuck Jordan
(702) 735-7001 (303) 471-5943
H.L. LANZET INC.
Herbert Lanzet/DeeDee Lanzet
(212) 687-0061
|
